Real-world effectiveness and safety of direct-acting antivirals in hepatitis C virus patients with mental disorders

Table 2 Characteristics of liver disease in patients with chronic hepatitis C with (group A) and without (group B) psychiatric disorders, %, n

Parameters	All patients (n = 14272)	Group A (n = 942)	Group B (n = 13330)	P value
Genotype
1a	4.4 (633)	4.1 (39)	4.5 (594)	0.649 (χ2 = 0.2)
1b	77.3 (11029)	67.8 (639)	77.9 (10390)	< 0.0001 (χ2 = 51.2)
1	2.1 (303)	2.4 (23)	2.1 (280)	0.483 (χ2 = 0.5)
2	0.2 (29)	0.2 (2)	0.2 (27)	> 0.948 (χ2 = 0.004)
3	11.1 (1580)	17.5 (165)	10.6 (1415)	< 0.0001 (χ2 = 42.6)
4	4.9 (695)	8.0 (74)	4.7 (621)	< 0.0001 (χ2 = 19.4)
5	0.007 (1)	0.0 (0)	0.007 (1)	1.0
6	0.01 (2)	(0.0) 0	0.01 (2)	1.012
Liver fibrosis
F0	2.5 (361)	1.4 (13)	2.6 (348)	0.02 (χ2 = 5.4)
F1	40.8 (5831)	34.8 (328)	41.3 (5503)	< 0.0001 (χ2 = 15.2)
F2	19.2 (2743)	21.0 (198)	19.1 (2545)	0.147 (χ2 = 2.1)
F3	13.5 (1925)	13.2 (124)	13.5 (1801)	0.763 (χ2 = 0.09)
F4	23.9 (3412)	29.6 (279)	23.5 (3133)	< 0.0001 (χ2 = 18.1)
Child-Pugh
Child-Pugh-B	2.8 (398)	4.4 (41)	2.7 (357)	0.003 (χ2 = 9.1)
Child-Pugh-C	0.2 (23)	0.4 (4)	0.1 (19)	0.061
HCC history	1.3 (191)	1.2 (11)	1.3 (180)	0.637 (χ2 = 0.2)
Coinfection
HIV	5.9 (848)	9.1 (86)	5.7 (762)	< 0.0001 (χ2 = 18.4)
HBV	13.5 (1933)	17.5 (165)	13.3 (1768)	0.0002 (χ2 = 13.6)
HIV/HBV	1.6 (225)	3.4 (32)	1.4 (193)	< 0.0001 (χ2 = 21.6)

The reported P value relates to Pearson’s chi-square test or Fisher’s exact test if the number of observations in the category was less than 10. HCC: Hepatocellular carcinoma; HIV: Human immunodeficiency virus; HBV: Hepatitis B virus.